GB0023203D0 - Vaccination method - Google Patents

Vaccination method

Info

Publication number
GB0023203D0
GB0023203D0 GBGB0023203.3A GB0023203A GB0023203D0 GB 0023203 D0 GB0023203 D0 GB 0023203D0 GB 0023203 A GB0023203 A GB 0023203A GB 0023203 D0 GB0023203 D0 GB 0023203D0
Authority
GB
United Kingdom
Prior art keywords
vaccination method
replicating
epitopes
inducing
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0023203.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB0023203.3A priority Critical patent/GB0023203D0/en
Publication of GB0023203D0 publication Critical patent/GB0023203D0/en
Priority to US10/345,000 priority patent/US20040018177A1/en
Priority to AU2001286109A priority patent/AU2001286109B2/en
Priority to ES01965468T priority patent/ES2345604T3/es
Priority to PCT/GB2001/004116 priority patent/WO2002024224A2/en
Priority to EP01965468A priority patent/EP1320379B8/en
Priority to AT01965468T priority patent/ATE465750T1/de
Priority to JP2002528294A priority patent/JP5102930B2/ja
Priority to AU8610901A priority patent/AU8610901A/xx
Priority to CA2422094A priority patent/CA2422094C/en
Priority to DE60141969T priority patent/DE60141969D1/de
Priority to GB0308955A priority patent/GB2384709B/en
Priority to US10/079,167 priority patent/US20030138454A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0023203.3A 1997-06-09 2000-09-21 Vaccination method Ceased GB0023203D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB0023203.3A GB0023203D0 (en) 2000-09-21 2000-09-21 Vaccination method
GB0308955A GB2384709B (en) 2000-09-21 2001-09-13 Compositions for stimulating a CD4+ T cell response for use in a prime boost vaccination method
AT01965468T ATE465750T1 (de) 2000-09-21 2001-09-13 Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell- immunantwort gegen antigen
AU2001286109A AU2001286109B2 (en) 2000-09-21 2001-09-13 Use of replication-deficient poxvirus vector to boost CD4+T cell immune response to antigen
ES01965468T ES2345604T3 (es) 2000-09-21 2001-09-13 Uso del vector virus pox carente de replica para impulsar la respuesta inmune de celula t cd4+ al antigeno.
PCT/GB2001/004116 WO2002024224A2 (en) 2000-09-21 2001-09-13 Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen
EP01965468A EP1320379B8 (en) 2000-09-21 2001-09-13 Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen
US10/345,000 US20040018177A1 (en) 2000-09-21 2001-09-13 Vacination method
JP2002528294A JP5102930B2 (ja) 2000-09-21 2001-09-13 ワクチン接種方法
AU8610901A AU8610901A (en) 2000-09-21 2001-09-13 Vaccination method
CA2422094A CA2422094C (en) 2000-09-21 2001-09-13 Vaccination method
DE60141969T DE60141969D1 (de) 2000-09-21 2001-09-13 Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell-immunantwort gegen antigen
US10/079,167 US20030138454A1 (en) 1997-06-09 2002-02-19 Vaccination method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0023203.3A GB0023203D0 (en) 2000-09-21 2000-09-21 Vaccination method

Publications (1)

Publication Number Publication Date
GB0023203D0 true GB0023203D0 (en) 2000-11-01

Family

ID=9899889

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0023203.3A Ceased GB0023203D0 (en) 1997-06-09 2000-09-21 Vaccination method
GB0308955A Expired - Fee Related GB2384709B (en) 2000-09-21 2001-09-13 Compositions for stimulating a CD4+ T cell response for use in a prime boost vaccination method

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0308955A Expired - Fee Related GB2384709B (en) 2000-09-21 2001-09-13 Compositions for stimulating a CD4+ T cell response for use in a prime boost vaccination method

Country Status (10)

Country Link
US (1) US20040018177A1 (https=)
EP (1) EP1320379B8 (https=)
JP (1) JP5102930B2 (https=)
AT (1) ATE465750T1 (https=)
AU (2) AU8610901A (https=)
CA (1) CA2422094C (https=)
DE (1) DE60141969D1 (https=)
ES (1) ES2345604T3 (https=)
GB (2) GB0023203D0 (https=)
WO (1) WO2002024224A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
EP1450854A2 (en) * 2001-11-30 2004-09-01 Isis Innovation Limited Vaccine
NZ536592A (en) 2002-04-19 2007-01-26 Bavarian Nordic As Modified vaccinia virus ankara for the vaccination of neonates
US20050123561A1 (en) * 2002-05-20 2005-06-09 Mitsuo Honda Radio lan access authentication system
JP2005537793A (ja) 2002-09-05 2005-12-15 バヴァリアン・ノルディック・アクティーゼルスカブ 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法
DE10249390A1 (de) * 2002-10-23 2004-05-13 Ruprecht-Karls-Universität Heidelberg Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
GB2421025A (en) * 2004-12-09 2006-06-14 Oxxon Therapeutics Ltd HSV vaccination vectors
WO2006120474A2 (en) * 2005-05-13 2006-11-16 Oxxon Therapeutics Ltd Compositions for inducing an immune response against tumor antigens
EP2125868B1 (en) * 2007-02-28 2015-06-10 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
MX2017002890A (es) 2014-09-03 2017-11-13 Bavarian Nordic As Métodos y composiciones para potenciar respuestas inmunitarias.
HUE065565T2 (hu) 2014-09-03 2024-06-28 Bavarian Nordic As Módszerek és készítmények filovírus fertõzés elleni védõ immunitás elõidézésére
ES2865150T3 (es) 2014-09-26 2021-10-15 Beth Israel Deaconess Medical Ct Inc Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
CN105753989A (zh) * 2014-12-15 2016-07-13 牛津疫苗医学生物科技（英国）有限公司 人工多抗原融合蛋白及其制备和应用
US10881725B2 (en) 2016-01-29 2021-01-05 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine
JP7250520B2 (ja) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えアルテリウイルスレプリコン系およびその使用
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
CA3035759A1 (en) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR102718353B1 (ko) 2016-10-17 2024-10-15 얀센 파마슈티칼즈, 인코포레이티드 재조합 바이러스 레플리콘 시스템 및 그의 용도
JP7788787B2 (ja) 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 遺伝子発現増強のための組成物および方法
US11173204B2 (en) 2017-04-06 2021-11-16 Janssen Vaccines & Prevention B.V. MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
US20190083620A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
CN111741766A (zh) 2017-12-19 2020-10-02 杨森科学爱尔兰无限公司 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
WO2019143949A2 (en) 2018-01-19 2019-07-25 Synthetic Genomics, Inc. Induce and enhance immune responses using recombinant replicon systems
KR20210074314A (ko) 2018-10-08 2021-06-21 얀센 파마슈티칼즈, 인코포레이티드 생체치료제의 투여를 위한 알파바이러스 기반 레플리콘
TW202110476A (zh) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
CN116367854A (zh) 2020-07-08 2023-06-30 杨森科学爱尔兰无限公司 针对hbv的rna复制子疫苗
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
EP4316514A1 (en) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2
WO2024063788A1 (en) * 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
JP2025533541A (ja) * 2022-09-23 2025-10-07 ビオンテック・ソシエタス・エウロパエア 肝病期抗原の送達のための組成物及び関連方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US7094408B2 (en) * 2000-04-28 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf

Also Published As

Publication number Publication date
JP2004509149A (ja) 2004-03-25
ES2345604T3 (es) 2010-09-28
AU2001286109B2 (en) 2006-12-14
WO2002024224A3 (en) 2002-06-13
GB2384709B (en) 2005-05-04
ATE465750T1 (de) 2010-05-15
AU8610901A (en) 2002-04-02
CA2422094C (en) 2011-04-19
EP1320379A2 (en) 2003-06-25
DE60141969D1 (de) 2010-06-10
EP1320379B1 (en) 2010-04-28
CA2422094A1 (en) 2002-03-28
GB0308955D0 (en) 2003-05-28
JP5102930B2 (ja) 2012-12-19
US20040018177A1 (en) 2004-01-29
GB2384709A (en) 2003-08-06
WO2002024224A2 (en) 2002-03-28
EP1320379B8 (en) 2010-06-02

Similar Documents

Publication Publication Date Title
AU8610901A (en) Vaccination method
DK0865297T3 (da) Vaccinesammensætninger til intranasal administration omfattende chitosan og anvendelsen deraf
AP2002002592A0 (en) Vaccine for the prophylactic or therapeutic immunization against HIV.
EE200200507A (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
ATE350057T1 (de) Impfstoffzusammesetzung
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
AU2002338832A1 (en) Vaccine
CY1111636T1 (el) Εμβολιο που περιεχει gp120 και nef kai/´h tat για ανοσοποιηση εναντι hiv
EP0934083A4 (en) IMPROVED VACCINES
WO2002068654A3 (es) Poxvirus recombinantes para proteinas quimericas del virus de la inmunodeficiencia humana
AU5423898A (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
ATE248601T1 (de) Impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4
MXPA02012192A (es) Preparacion activa de lavado.
WO1998040097A3 (en) Bovine respiratory and enteric coronavirus as a vaccine
WO1997011669A3 (en) MHC-class II restricted melanoma antigens and their use in therapeutic methods
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
SE9600436D0 (sv) Vaccine against hantavirus
WO2002012272A8 (en) Therapeutic anti-melanoma compounds
WO2003037264A3 (en) Therapeutic anti-hiv (vpr) compounds
UA67259A (en) Strain pestivirus bovine viraldiarrhoea "bk-1" for the preparation of vaccines and diagnosticums
WO2003051285A3 (en) Therapeutic anti-hiv (iv9) compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)